The International Equity ADR composite rose 3.0% gross of fees in the second quarter, behind the 7.0% gain of the MSCI ACWI ex US Index. In Communication Services, Tencent delivered a second consecutive quarter of double-digit revenue and profit growth. Japan was the largest detractor, with Chugai and Sysmex weighing on results.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ALC's UNITY VCS shows faster, more efficient cataract and vitreoretinal surgery results, lifting shares after study presentations.
ALC's Q2 earnings top estimates but revenues fall short, sending shares down more than 10% as margins tightened and 2025 sales outlook narrowed.
Alcon Inc. (NYSE:ALC ) Q2 2025 Earnings Conference Call August 20, 2025 8:00 AM ET Call Participants Daniel Cravens - Vice President of Investor Relations David J. Endicott - CEO & Director Timothy C.
The company said it expects a $100 million hit from tariffs this year.
The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Get a deeper insight into the potential performance of Alcon (ALC) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.
ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition.
FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.
Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).